Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on £20 million growth capital investment in Mereo BioPharma
Charles Russell Speechlys have advised Kreos Capital and Silicon Valley Bank on a £20 million growth capital investment in Mereo BioPharma, a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma was established to address the R&D and financial challenges faced by an increasing number of large pharmaceutical and biotech companies, and to optimise drug development and ensure that promising drug candidates fulfil their potential.
Mereo BioPharma announced to the market that it will use the financing to increase its operational and development flexibility.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate), Amelly Kok (Associate) and Olivia Mackie (Associate) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking Team.”
News & Insights
Charles Russell Speechlys advises Liberum Capital on the move of Oakley Capital Investments Ltd from AIM to the Specialist Fund Segment of the LSE Main Market
Charles Russell Speechlys advised Liberum Capital - financial advisor, corporate broker to OCI - on moving from AIM to LSE’s Main Market.
Charles Russell Speechlys advises Duke Royalty Limited (AIM: DUKE) on £30 Million Debt Facility from Honeycomb Investment Trust PLC
Charles Russell Speechlys advised Duke Royalty Limited on a new £30m revolving credit facility agreement.
Charles Russell Speechlys advises IT Lab on the acquisition of Mirus IT
Charles Russell Speechlys advised IT Lab on the acquisition of Milton Keynes based managed services provider Mirus IT.
British Private Equity Awards 2019: Charles Russell Speechlys team shortlisted for Law Firm of the Year
The Private Equity team has been shortlisted for the Law Firm of the Year – Transactions category at the British Private Equity Awards 2019.